Clinigen Group Share Price (CLIN)
| Bid price | 920.50 | Open price | 0.00 |
|---|---|---|---|
| Ask price | 923.00 | Prev close | 920.50 |
| High price | 0.00 | Spread | 0.00% |
| Low price | 0.00 | Volume | 0 |
Register now for FREE live Clinigen Group share prices, Clinigen Group stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Clinigen Group Level 2 Data, indepth research tools and investor commentary for Clinigen Group (CLIN) and other London Stock Exchange equities.
Clinigen Group Share Price Chart
Register now for FREE Clinigen Group share price charts
Clinigen Group Share Price Information
| Name | Clinigen Group | Epic | CLIN |
|---|---|---|---|
| Sector | Pharmaceuticals & Biotechnology | ISIN | GB00B89J2419 |
| Activites | Clinigen Group plc is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. | Index | n/a |
Clinigen Group Key Numbers
| Latest Share Price (p) | 0.00 | Net Gearing (%) | 42.17 |
|---|---|---|---|
| Market Capitalisation (£m) | 1,215.74 | Gross Gearing (%) | 47.61 |
| Shares in issue (m) | 132.43 | Debt Ratio | 36.83 |
| P/E Ratio | 40.09 | Debt-to-Equity Ratio | 0.64 |
| Total dividends per share (p) | 5.60 | Assets / Equity Ratio | 1.91 |
| Dividend Yield (%) | 0.00 | Price to book value | 3.48 |
| Dividend cover (x) | 4.09 | ROCE (%) | 6.49 |
| Earning per share (p) | 22.90 | EPS Growth (%) | 593.94 |
| 52 week high / low | 1,067.00 / 716.00 | DPS Growth (%) | 12.00 |
Clinigen Group Director Deals
| Dec.Date | Type | Director | Pos | No. of Shares |
|---|---|---|---|---|
| 01/10/2018 | PLAC | Shaun Chilton | CEO | 7,101 |
| 01/10/2018 | PLAC | Anne Hyland | NED | 4,142 |
| 24/11/2017 | SELL | Chris Rigg | RES | 4,955 |
| 16/10/2017 | SELL | Shaun Chilton | CEO | 100,000 |
| 03/10/2017 | SELL | John Bacon | RES | 250,000 |
Clinigen Group Company News
Broker Forecast - Peel Hunt issues a broker note on Clinigen Group
Peel Hunt today reaffirms its buy investment rating on Clinigen Group (LON:CLIN) and raised its price target to 1390p (from 1300p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
Clinigen to acquire US rights to Proleukin
RNS Number : 8211P Clinigen Group plc 13 February 2019 13 February 2019 Clinigen to acquire US rights to Proleukin® Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services company, has signed an agreement with...
Notification of half year results date
RNS Number : 6853P Clinigen Group plc 12 February 2019 12 February 2019 Notification of half year results date Clinigen Group plc ('Clinigen' or the 'Group', AIM: CLIN), the global pharmaceutical and services company, will announce its half year...
More Clinigen Group Company News >>
Register now for FREE Clinigen Group company news
Clinigen Group Share Price Discussions
Clinigen Group plc (CLIN)
Dealings in Clinigen shares are expected to commence on AIM at 8.00am on Tuesday 25 September 2012, under the ticker symbol CLIN Clinigen is a rapidly-growing specialty pharmaceutical and services company, with one clear aim: to deliver the right drug to the right patient at the right...
Register now for FREE Clinigen Group share price discussions